Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and named a new CEO.

Shares of Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Shares in Novo Nordisk plunged as much as 30% after the Danish drugmaker cut its guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy weight-loss drug.